MedTrace Logo

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2015-05-20

No results posted yet for this study

Summary

This study has been designed in compliance with the ICH-E14 guideline (2005) to evaluate the effect of ANX-188 at therapeutic and supratherapeutic concentrations on cardiac repolarization, specifically, Fridericia's QT-Interval (QTcF)

Conditions

  • Healthy

Interventions

DRUG

ANX-188 Therapeutic Dose

DRUG

ANX-188 Supratherapeutic dose

DRUG

Saline

DRUG

Moxifloxacin

Sponsors & Collaborators

  • Mast Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Edwin L Parsley, D.O. · Mast Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-04-30
Completion
2013-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01790087 on ClinicalTrials.gov